Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes.

The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale. The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

• The Company offers comprehensive  one-stop  service  capabilities  across  the  drug  life  cycle  (drug  discovery,  development  and manufacturing) for both small molecules and biologics and it is the fastest growing Indian CRDMO.
• Its innovation-focused approach  has  enabled  to  offer  a  spectrum  of  technologically  advanced  solutions  across modalities and manufacturing practices.
• Differentiated business  model  catering  to  the  needs  of  small  pharmaceutical  and  emerging  biotech  companies,  from discovery to commercial manufacturing.
• Long-standing relationships with a large, diversified and loyal customer base.
• Wide specialty  ingredients  portfolio,  well  positioned  to  capitalize  on  the  large  market  opportunity  for  niche  specialty ingredients such as GLP-1, fermentation-based products, probiotics, enzymes, nutritional actives, vitamin analogues and biosimilars.
• Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record.
• Demonstrated industry-leading  growth,  profitability  and  capital  efficiency  from  Fiscal  2024 to  Fiscal  2025alongside  a robust growth pipeline.
• Professional and experienced leadership team supported by a qualified scientific talent pool.

The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.

At the upper band of IPO Rs. 570, the stock is valued at 70.73 times. Hence, Well-informed investors subscribe for long term.